0001178913-22-004098.txt : 20221117
0001178913-22-004098.hdr.sgml : 20221117
20221117165623
ACCESSION NUMBER: 0001178913-22-004098
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221116
FILED AS OF DATE: 20221117
DATE AS OF CHANGE: 20221117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mor George Adi
CENTRAL INDEX KEY: 0001851069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 221399176
MAIL ADDRESS:
STREET 1: 15 KAFRISIN ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6901658
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
ownership.xml
X0306
4
2022-11-16
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001851069
Mor George Adi
15 KAFRISIN ST.
TEL AVIV
L3
6901658
ISRAEL
1
1
0
0
Chief Scientific Officer
American Depositary Shares
2022-11-16
4
S
0
324775
2.0848
D
324775
D
American Depositary Shares
2022-11-16
4
S
0
257248
2.0848
D
257247
I
By Spouse
Option to Purchase American Depositary Shares
1.49
2018-03-15
4
A
0
131698
0
A
2028-03-15
American Depositary Shares
131698
131698
D
Option to Purchase American Depositary Shares
0.8
2016-10-28
4
A
0
33725
0
A
2026-10-27
American Depositary Shares
33725
33725
I
By Kobi George, the Reporting Person's spouse
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
These options have vested and are exercisable as of the date hereof.
These options have vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.
/s/ David S. Glatt, Attorney-in-Fact for Adi Mor and Kobi George.
2022-11-17